Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple ascending dose study of NA808 in chronic hepatitis C
jRCT2080221056Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2010
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of NA808 in chronic hepatitis C (CHC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
NA808
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080221056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221056.